223 related articles for article (PubMed ID: 22744885)
1. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.
Talbot GH; Powers JH; Fleming TR; Siuciak JA; Bradley J; Boucher H;
Clin Infect Dis; 2012 Oct; 55(8):1114-21. PubMed ID: 22744885
[TBL] [Abstract][Full Text] [Related]
2. Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.
Talbot GH; Powers JH; Hoffmann SC;
Clin Infect Dis; 2016 Mar; 62(5):603-7. PubMed ID: 26668337
[TBL] [Abstract][Full Text] [Related]
3. A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Toerner JG; Burke L; Komo S; Papadopoulos E
Clin Infect Dis; 2012 Oct; 55(8):1122-3. PubMed ID: 22744886
[No Abstract] [Full Text] [Related]
4. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
5. Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.
Talbot GH
Clin Infect Dis; 2021 Nov; 73(9):e2613-e2615. PubMed ID: 32584958
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
Cornely OA; File TM; Garrity-Ryan L; Chitra S; Noble R; McGovern PC
Int J Antimicrob Agents; 2021 Feb; 57(2):106263. PubMed ID: 33326848
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
[TBL] [Abstract][Full Text] [Related]
8. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
Corey GR; Stryjewski ME
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623
[TBL] [Abstract][Full Text] [Related]
9. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
[TBL] [Abstract][Full Text] [Related]
10. Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
Leviton IM; Amodio-Groton M
Clin Drug Investig; 2022 Mar; 42(3):193-197. PubMed ID: 35192150
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Casapao AM; Steed ME; Levine DP; Rybak MJ
Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
[TBL] [Abstract][Full Text] [Related]
12. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Chopra T; Sandhu A; Theriault N; Meehan J; Tillotson G
Future Microbiol; 2020 Sep; 15():1319-1333. PubMed ID: 32959689
[TBL] [Abstract][Full Text] [Related]
13. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
[TBL] [Abstract][Full Text] [Related]
14. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Maggiore C; Pasquale T; Cole P; Friedland HD
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
[TBL] [Abstract][Full Text] [Related]
15. [Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
Nikitin AV
Antibiot Khimioter; 2011; 56(7-8):47-9. PubMed ID: 22359871
[No Abstract] [Full Text] [Related]
16. Omadacycline in treating community-based infections: a review and expert perspective.
Sakoulas G; Nowak M; Geriak M
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):255-265. PubMed ID: 36718489
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
18. [Uncertainties in the therapy of infectious diseases].
Heimann D
Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S82. PubMed ID: 25429535
[No Abstract] [Full Text] [Related]
19. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
Dillon C; Guarascio AJ; Covvey JR
Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
[TBL] [Abstract][Full Text] [Related]
20. Omadacycline: First Global Approval.
Markham A; Keam SJ
Drugs; 2018 Dec; 78(18):1931-1937. PubMed ID: 30471003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
